Cost-Utility Analysis of Vasoconstrictors Plus Albumin in the Treatment of Thai Patients with Type 1 Hepatorenal Syndrome.
Sermsiri SangroongruangsriKankamon KittrongsiriPhunchai CharatcharoenwitthayaAbhasnee SobhonslidsukUsa ChaikledkaewPublished in: ClinicoEconomics and outcomes research : CEOR (2021)
The T+A and N+A treatments would not be cost-effective compared to BSC in the Thai setting.
Keyphrases